Epirubicin, cisplatin plus ifosfamide versus standard chemotherapeutic regimens for advanced/unresectable primary thoracic sarcomas.
Rodriguez-Cid JR, Juarez-Vignon Whaley JJ, Sánchez-Domínguez G, Guzmán-Casta J, Carrasco-CaraChards S, Guzmán-Huesca J, Riera-Sala R, Sánchez-Ríos CP, Cruz-Zermeño M, Seidman-Sorsby A, de Jesús Rodríguez-Zea I, Alatorre-Alexander JA, Martínez-Barrera LM, Santillán-Doherty PJ, Godina-Flores A, Imaz-Olguin V, Sosa-Sánchez R, Green-Renner D.
Rodriguez-Cid JR, et al. Among authors: sanchez rios cp.
J Cancer Res Clin Oncol. 2023 Aug;149(9):5479-5491. doi: 10.1007/s00432-022-04454-8. Epub 2022 Dec 4.
J Cancer Res Clin Oncol. 2023.
PMID: 36463530